Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleLow dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : A double-blind placebo-controlled cross-over trial.
Author(s)Wissel J, Haydn T, Muller J, Brenneis C, Berger T, Poewe W, Schelosky LD.
Journal, Volume, IssueJ Neurol. 2006 Sep 20; [Epub ahead of print]
Major outcome(s)Significant reduction of pain
IndicationMultiple sclerosis;PainAbstract
MedicationNabilone

About 30% of patients with chronic upper motor neuron syndrome (UMNS) suffer from disabling spasticity-related pain not sufficiently correctable by conventional treatment. Delta9-tetrahydrocannabinol (Delta(9)-THC) was reported to add benefit in the treatment of pain in patients with multiple sclerosis (MS). The question arose whether synthetic cannabinoids with lower potential for psychotropic side effects could be effective as well. To evaluate the safety and efficacy of low dose treatment with the synthetic cannabinoid Nabilone (1 mg per day) on spasticity-related pain a placebo-controlled double-blind crossover trial was performed.11 out of 13 included patients completed the study. The 11-Point-Box-Test showed a significant decrease of pain under Nabilone (p < 0.05), while spasticity, motor function and activities of daily living did not change. 5 patients reported side effects: one moderate transient weakness of the lower limbs (Nabilone phase, drop out), three mild drowsiness (two Nabilone, one placebo) and one mild dysphagia (placebo). One patient was excluded from the study due to an acute relapse of multiple sclerosis (Nabilone phase, drop out).Nabilone 1 mg per day proved to be a safe and easily applicable option in the care of patients with chronic UMNS and spasticity-related pain otherwise not controllable.

Route(s)Oral
Dose(s)1 mg/day
Duration (days)28
Participants13 patients with pain related to spasticity
DesignControlled study
Type of publicationMedical journal
Address of author(s)Dept. of Neurology, University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
Full text

[Back to Overview]  [IACM Homepage]


up